Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor DDI Study with CYP and Transporter Substrates
NCT05981365Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of voxelotor in sickle cell disease (SCD) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Apr 2023; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05981365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981365.